Suppr超能文献

根据初诊时原发肿瘤的大小判断肾肿瘤的转移潜能。

Metastatic potential of a renal mass according to original tumour size at presentation.

机构信息

Department of Urology, Mayo Clinic, Rochester, MN, USA.

出版信息

BJU Int. 2012 Jan;109(2):190-4; discussion 194. doi: 10.1111/j.1464-410X.2011.10184.x. Epub 2011 May 9.

Abstract

OBJECTIVE

To determine the metastatic potential of renal masses based on original tumour size.

MATERIALS AND METHODS

We identified 2651 patients who had undergone surgical resection for a unilateral, sporadic renal tumour between 1990 and 2006. Associations of tumour size with synchronous metastasis at presentation [M1 renal cell carcinoma (RCC)] and development of metastases, death from RCC, and death from any cause after surgery were evaluated using logistic and Cox proportional hazards regression.

RESULTS

Of the 2651 patients studied, 182 (6.9%) presented with M1 RCC. Tumour size was significantly greater in patients with M1 RCC than in patients with M0 RCC (a median size of 10 vs 4.5 cm; P < 0.001). Only 1 of the 629 patients (0.2%) with a tumour <3 cm had M1 RCC and that tumour was 2.5 cm. The risk of M1 RCC increased from 1.1% for patients with tumours 3-3.9 cm to 16.5% for patients with tumours ≥7 cm. Of the 2124 patients with M0 RCC, 430 developed distant metastases at a median (range) of 1.4 (0.1-16.2) years after surgery. Only 9 of the 498 patients (1.8%) with a tumour <3 cm developed distant metastases after surgery. Each 1-cm increase in tumour size increased the risk of death from RCC by 20%[hazard ratio (HR) 1.20; 95% confidence interval (CI) 1.18-1.22; P < 0.001] and death from any cause by 10% (HR 1.10; 95% CI 1.09-1.12; P < 0.001). For the 1346 patients who were still alive at last follow-up, the median (range) duration of follow-up was 6.9 (0.1-19.7) years.

CONCLUSIONS

Tumour size is significantly associated with metastases in patients with renal masses. Patients with tumours <3 cm have a low risk of synchronous metastatic disease.

摘要

目的

根据原始肿瘤大小确定肾脏肿块的转移潜能。

材料和方法

我们确定了 1990 年至 2006 年间接受单侧、散发性肾肿瘤手术切除的 2651 名患者。使用逻辑和 Cox 比例风险回归评估肿瘤大小与同期转移(M1 肾细胞癌[RCC])和转移发展、RCC 死亡以及手术后任何原因死亡的相关性。

结果

在研究的 2651 名患者中,182 名(6.9%)患者表现为 M1 RCC。M1 RCC 患者的肿瘤大小明显大于 M0 RCC 患者(中位数大小分别为 10cm 和 4.5cm;P <0.001)。在 629 名肿瘤<3cm 的患者中,仅有 1 名患者发生 M1 RCC,肿瘤大小为 2.5cm。肿瘤为 3-3.9cm 的患者 M1 RCC 风险从 1.1%增加到肿瘤≥7cm 的患者的 16.5%。在 2124 名 M0 RCC 患者中,430 名患者在手术后中位数(范围)1.4 年(0.1-16.2 年)时发生远处转移。仅有 498 名肿瘤<3cm 的患者中,有 9 名患者在手术后发生远处转移。肿瘤大小每增加 1cm,RCC 死亡风险增加 20%[风险比(HR)1.20;95%置信区间(CI)1.18-1.22;P <0.001],任何原因死亡风险增加 10%(HR 1.10;95%CI 1.09-1.12;P <0.001)。在最后一次随访时仍存活的 1346 名患者中,中位(范围)随访时间为 6.9 年(0.1-19.7 年)。

结论

肿瘤大小与肾肿瘤患者的转移显著相关。肿瘤<3cm 的患者发生同步转移性疾病的风险较低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验